Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

Blood Cancer J. 2014 Aug 29;4(8):e242. doi: 10.1038/bcj.2014.62.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5 / genetics*
  • Disease-Free Survival
  • Female
  • Humans
  • Lenalidomide
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / mortality
  • Myelodysplastic Syndromes* / pathology
  • Risk Factors
  • Survival Rate
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*

Substances

  • Angiogenesis Inhibitors
  • Thalidomide
  • Lenalidomide